MEG Election Results
Congratulations to Andrew T. Chan, MD, MEG Chairperson-elect 2020-2021
Our thanks to Andrew T. Chan, MD, and Michele L. Cote, PhD, for standing for election, and to the MEG membership for participating in the election. We congratulate Dr. Chan on his election as MEG chairperson-elect. Dr. Chan will assume the office of chairperson-elect at the AACR Annual Meeting 2020, April 24-29, in San Diego, California.
MD, Harvard Medical School, 1997
MPH, Harvard School of Public Health, 2004
Research Interests / Vision Statement
I am honored to be elected chair of the MEG Working Group. As a gastroenterologist and trained epidemiologist, I lead clinical and translational research in gastrointestinal cancers with a focus on chemoprevention and the gut microbiome. My research is at the intersection of epidemiology, the clinic, and the laboratory, with significant programs based on large population-based cohorts, clinical patient populations, and at the bench using patient-derived model systems. In 2019, I was honored with the AACR-Waun Ki Hong Outstanding Achievement in Translational and Clinical Cancer Research. Over the last 10 years, I have served AACR in varying capacities on the Planning Committee and the Scientific Review committee for the Annual Meeting and “Frontiers in Cancer Prevention” meeting. I serve as special section editor for Gastroenterology and am a member of the editorial boards of JNCI, Cancer Prevention Research and Cancer Epidemiology, Biomarkers and Prevention. I have also been honored for my role in mentoring young investigators, both locally and nationally. As a clinical gastroenterologist, I specialize in familial gastrointestinal cancer syndromes and cancer prevention. Collectively, these experiences inform my vision as chair for MEG. My priorities for the AACR Annual Meeting and special topic conferences include 1) enhancing cross-disciplinary programming with a particular focus on engaging clinicians; 2) illustrating the unique role of the molecular epidemiologist in bridging fundamental bench scientists with patient-oriented researchers; and 3) increasing the visibility of young investigators, particularly those underrepresented in cancer research.